Rhabdomyolysis in a Hospitalized 16-Year-Old Boy: A Rarely Reported Underlying Cause

Singh, Rishika; Patel, Dilip R.; Pejka, Sherry

doi:10.1155/2016/7873813

Cited by 14 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The other case, a 19-year-old man, was reported by Isaacson et al 9 There have been limited reports of levetiracetam-induced rhabdomyolysis in children. Incecik et al 5 reported a 13-yearold patient and Singh et al 10 reported this clinical situation in a 16-year-old adolescent patient. Carnovale et al 6 analyzed reports from Food and Drug Administration Adverse Event Reporting System database and they detected 48 reports of levetiracetam-induced rhabdomyolysis with an increased trend in reporting in year to year and eight of these reports involved children.…”

Section: Discussionmentioning

confidence: 93%

Levetiracetam Treatment-Associated Acute Rhabdomyolysis in an Adolescent

Aslan

Yıldızdaş

Huseyınlı

et al. 2020

J Pediatr Intensive Care

View full text Add to dashboard Cite

Etiology of rhabdomyolysis includes hereditary muscle enzyme deficiencies, trauma, viral infections, excessive exercise, hypothyroidism, and medications such as colchicine, lithium, and statins. Several studies have reported that various antiepileptic drugs may induce rhabdomyolysis. Levetiracetam is one of the antiepileptic drugs implicated in the etiology of rhabdomyolysis. Herein, we present a case of rhabdomyolysis in an adolescent treated with levetiracetam. We wanted to draw attention to the increasing trend of levetiracetam-associated rhabdomyolysis frequency in pediatric patients.

show abstract

Section: Discussionmentioning

confidence: 93%

Levetiracetam Treatment-Associated Acute Rhabdomyolysis in an Adolescent

Aslan

Yıldızdaş

Huseyınlı

et al. 2020

J Pediatr Intensive Care

View full text Add to dashboard Cite

show abstract

“…None of the levetiracetam users who developed AKI had evidence of rhabdomyolysis. Rhabdomyolysis with levetiracetam use has been documented in nine case reports in the literature ( Supplemental Table 11), within 2 weeks of drug initiation, and with a higher prevalence reported in Japanese patients (7,13,(36)(37)(38)(39)(40)(41)(42). Although prolonged seizures can independently cause rhabdomyolysis, two case reports of AKI have been attributed to rhabdomyolysis secondary to levetiracetam use (7,13).…”

Section: Discussionmentioning

confidence: 99%

“…We performed a search of bibliographic databases and identified only eight studies, all case reports, that suggested a greater risk of AKI with levetiracetam (Supplemental Table 3). In these reports, four cases of AKI were attributed to interstitial nephritis, two to rhabdomyolysis, and one to a pharmacokinetic interaction with methotrexate (7)(8)(9)(10)(11)(12)(13)(14). Therefore, to provide additional safety data we conducted this population-based cohort study to determine whether levetiracetam use is associated with a higher risk of AKI compared with nonuse.…”

Section: Introductionmentioning

confidence: 99%

Population-Based Study of Risk of AKI with Levetiracetam

Yau

Burneo

Jandoc

et al. 2018

CJASN

View full text Add to dashboard Cite

Background and objectives Regulatory agencies warn about the risk of AKI with levetiracetam use on the basis of information from case reports. We conducted this study to determine whether new levetiracetam use versus nonuse is associated with a higher risk of AKI.Design, setting, participants, & measurements This was a population-based retrospective cohort study of adults with epilepsy in Ontario, Canada. Patients who received a new outpatient prescription for levetiracetam between January 1, 2004 and March 1, 2017 were matched to two nonusers on stage of CKD, recorded seizure in the prior 90 days, and logit of a propensity score for levetiracetam use. The primary outcome was a hospital encounter (emergency department visit or hospitalization) with AKI within 30 days of cohort entry. Secondary outcomes were AKI within 180 days and change in the concentration of serum creatinine. We assessed the primary outcome using health care diagnosis codes. We evaluated the change in the concentration of serum creatinine in a subpopulation with laboratory measurements. ResultsWe matched 3980 levetiracetam users to 7960 nonusers (mean age 55 years, 51% women). Levetiracetam use was not significantly associated with a higher risk of AKI within 30 days (13 [0.33%] events in levetiracetam users and 21 [0.26%] events in nonusers [odds ratio, 1.24; 95% confidence interval, 0.62 to 2.47]). Similarly, there was no significant association with AKI within 180 days (odds ratio, 0.70; 95% confidence interval, 0.43 to 1.13). The change in the concentration of serum creatinine did not significantly differ between levetiracetam users and nonusers. ConclusionsIn this population-based study levetiracetam use was not associated with a higher risk of AKI.

show abstract

“…Rhabdomyolysis has rarely been reported as an adverse effect of levetiracetam and until only eight cases have been reported, all in the setting of seizures- generalised tonic-clonic seizures or partial seizures with secondary generalisation 1 6–12. Details of these eight cases including our case are summarised in table 1.…”

Section: Discussionmentioning

confidence: 95%

Rhabdomyolysis: a rare adverse effect of levetiracetam

Thomas¹,

Mirza

Shaikh

et al. 2019

BMJ Case Rep

View full text Add to dashboard Cite

A 62-year-old previously healthy male was admitted with new onset generalised tonic-clonic seizures. Treatment was initiated with the antiepileptic levetiracetam and he had no further episodes of seizures. Creatine kinase (CPK) level was 1812 IU/L 12-hour postadmission. Despite good hydration, his CPK levels continued to rise dramatically and reached a level of 19 000 IU/L on day 5. This rise was unexplained as he did not have any further seizures and had a normal renal function. In the absence of other risk factors, the rare possibility of levetiracetam being responsible for the disproportionately high CPK was considered. Within 12 hours of withdrawal of levetiracetam, there was a downward trend in the CPK levels, with a 10-fold decrease in CPK levels over the next 4 days. This is only the ninth case reported in literature regarding this rare and potentially serious adverse effect of levetiracetam.

show abstract

Rhabdomyolysis in a Hospitalized 16-Year-Old Boy: A Rarely Reported Underlying Cause

Cited by 14 publications

References 14 publications

Levetiracetam Treatment-Associated Acute Rhabdomyolysis in an Adolescent

Levetiracetam Treatment-Associated Acute Rhabdomyolysis in an Adolescent

Population-Based Study of Risk of AKI with Levetiracetam

Rhabdomyolysis: a rare adverse effect of levetiracetam

Contact Info

Product

Resources

About